NeoGenomics (NASDAQ:NEO), traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.
The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests. By combining traditional cytogenetic analysis with cutting-edge genomic technologies, NeoGenomics aims to provide comprehensive test menus that inform disease classification, treatment selection and monitoring of minimal residual disease.
In addition to its clinical testing business, NeoGenomics supports pharmaceutical and biotechnology customers through its Pharma Services division. This segment specializes in clinical trial testing, companion diagnostic development and biomarker discovery programs that accelerate oncology drug development and enable enrollment across global trial sites. The company has established partnerships with leading life-science organizations to tailor assay workflows for translational research and late-stage clinical studies.
Founded in 2002, NeoGenomics has expanded both organically and through strategic acquisitions to become one of the largest pure-play oncology testing laboratories worldwide. Under the leadership of President and Chief Executive Officer Douglas VanOort, the organization continues to invest in high-throughput automation, digital pathology capabilities and bioinformatics infrastructure. NeoGenomics serves a diverse client base that includes community hospitals, academic medical centers, reference laboratories and pharmaceutical firms.
